Drug Profile
CFC 240
Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator CJ Corporation
- Class Antibacterials
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Jul 1998 No-Development-Reported for Bacterial infections in South Korea (Unknown route)
- 09 Jun 1995 Preclinical development for Bacterial infections in South Korea (Unknown route)